skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Current status of maintenance therapy for advanced ovarian cancer

Review

(3173) Views  (1375) Full article downloads

Authors: Joanie Mayer Hope, Stephanie V Blank

Published Date November 2009 Volume 2009:1 Pages 173 - 180
DOI: http://dx.doi.org/10.2147/IJWH.S4661

Joanie Mayer Hope, Stephanie V Blank

New York University School of Medicine, Division of Gynecologic Oncology, New York NY, USA

Abstract: Even after countered with and responding to maximal surgical and chemotherapy efforts, advanced ovarian cancer usually ultimately recurs. One strategy employed to forestall recurrence is maintenance chemotherapy, an extension of treatment following a complete response to conventional measures. Many agents have been studied and many more are currently under investigation in maintenance regimens. While phase III data suggest that taxane maintenance prolongs progression-free survival, no overall survival benefit has been established. This article reviews the current status of maintenance therapy for advanced ovarian cancer, including phase III evidence and new and upcoming trials.

Keywords: maintenance therapy, consolidation therapy, advanced ovarian cancer








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS
Tinidazole in the treatment of bacterial vaginosis
Prevention of cervical, vaginal, and vulval cancers: role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccine
Raising HDL cholesterol in women
Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy